L. Maiorino

发表

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group.

V. Lorusso, G. Comella, N. Panza, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of Adjuvant Treatment in Breast Cancer Women Aged More than 70: Italian Cooperative Group Experience

S. de Placido, A. de Matteis, A. Pluchinotta, 2002, Tumori.

Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.

G. Di Lorenzo, G. Facchini, G. Cartenì, 2015, Future oncology.

Acceptance and Adherence of Oral Endocrine Therapy in Women with Metastatic Breast Cancer: Exacampania Group Study

R. Addeo, L. Maiorino, A. Febbraro, 2015, The breast journal.

Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer

A. Russo, V. Formica, M. Roselli, 2017, Oncotarget.

Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey.

M. Caraglia, S. Palazzo, B. Vincenzi, 2014, Future oncology.

Weekly cisplatin-epirubicin-paclitaxel (PET) vs. triweekly epirubicin-paclitaxel (ET) in metastatic breast cancer (MBC). Interim analysis of the SICOG 9908 phase III trial.

R. Thomas, A. Russo, G. Comella, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine/cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC): a phase II multicenter trial

G. Luporini, A. Santoro, V. Lorusso, 1999 .

Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non small cell lung cancer (NSCLC)

A. Santoro, L. Maiorino, M. Santoro, 1994 .

Capecitabine plus oxaliplatin for the first‐line treatment of elderly patients with metastatic colorectal carcinoma

A. Gambardella, V. Lorusso, S. Tafuto, 2005, Cancer.

Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401

G. Filippelli, B. Massidda, P. Comella, 2009, Journal of Cancer Research and Clinical Oncology.

Thyroid cancer: different outcomes to chemotherapy according to tumour histology.

V. Gebbia, L. Biganzoli, L. Maiorino, 1995, European journal of cancer.

Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study

G. D'aiuto, F. Caponigro, A. Budillon, 1998, Breast Cancer Research and Treatment.

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

M. Caraglia, B. Vincenzi, R. Addeo, 2010, Cancer Chemotherapy and Pharmacology.

Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).

A. Gambardella, M. Ghiani, M. Roselli, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.

A. Bianco, G. Comella, N. Panza, 1996, British Journal of Cancer.

Interim analysis of a phase III trial comparing cisplatin, gemcitabine, and vinorelbine vs. either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non small-cell lung cancer. A Southern Italy Cooperative Oncology Group Study.

V. Lorusso, G. Comella, N. Panza, 2000, Clinical lung cancer.

Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.

F. Carpagnano, V. Lorusso, M. de Lena, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.

F. Carpagnano, C. Pacilio, V. Lorusso, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.

V. Lorusso, M. Roselli, G. Filippelli, 2005, Clinical colorectal cancer.

Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.

V. Lorusso, M. Roselli, G. Filippelli, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients

M. Guida, N. Panza, G. Filippelli, 2004, British Journal of Cancer.

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial.

S. Milani, A. de Matteis, A. Pluchinotta, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.

G. Luporini, A. Rossi, C. Gridelli, 1999, Journal of the National Cancer Institute.

Cisplatin–epirubicin–paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology group (SICOG) phase II study

G. D'aiuto, I. Capasso, M. Bonito, 2000, Breast Cancer Research and Treatment.

Cisplatin–epirubicin–paclitaxel weekly administration in advanced breast cancer: A phase I study of the Southern Italy Cooperative Oncology Group

G. D'aiuto, I. Capasso, M. Bonito, 1999, Breast Cancer Research and Treatment.

Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.

V. Torri, G. Scagliotti, M. Hetzel, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: the prospective observational scoop trial results

C. Gridelli, S. Pignata, B. Daniele, 2017, Anti-cancer drugs.

A. Russo, V. Formica, M. Roselli, 2021, Annals of palliative medicine.

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

G. Botti, P. Ascierto, E. Simeone, 2013, Journal of Translational Medicine.

FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study.

L. Mariani, V. Gebbia, G. Comella, 1998, British Journal of Cancer.

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

S. Barni, R. Labianca, G. Luporini, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A two-month cisplatin-epirubicin-paclitaxel (PET) weekly administration is highly effective in large operable breast cancer. Final analysis of a SICOG phase II study

R. Thomas, G. D'aiuto, M. Bonito, 2005 .

Management of anal cancer: our experience.

A. Santoro, L. Maiorino, M. Santoro, 1999, Journal of chemotherapy.

Gemcitabine plus epirubicin in advanced pancreatic cancer: a phase II multicenter trial.

G. Catalano, M. Orditura, G. Ianniello, 2001, Oncology reports.

Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.

S. Tafuto, F. De Vita, F. Del Gaizo, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study

S. Tafuto, B. Massidda, P. Comella, 2005, Cancer Chemotherapy and Pharmacology.

A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.

A. Gambardella, V. Lorusso, S. Tafuto, 2005, Critical reviews in oncology/hematology.

Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma

A. Gambardella, V. Lorusso, P. Comella, 2003, British Journal of Cancer.

Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study.

A. Rossi, C. Gridelli, T. Pedicini, 2000, Lung cancer.

Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.

A. Avallone, G. Filippelli, R. Costanzo, 2010, Lung cancer.

Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series

M. Caraglia, B. Vincenzi, R. Addeo, 2010, Cancer Chemotherapy and Pharmacology.

Irinotecan and Mitomycin C in 5-Fluorouracil-Refractory Colorectal Cancer Patients

A. Avallone, G. Comella, M. Biglietto, 2001, Oncology.

Vinorelbine (VNR) plus best supportive care (BSC) vs. BSC in the treatment of advanced non-small cell lung cancer (NSCLC) elderly patients (PTS). Results of a phase III randomized trial

A. Rossi, C. Gridelli, S. Monfardini, 1998 .

fotemustine (FM) and dacarbazine (DTIC) versus DTIC ± interferon α in advanced malignant melanoma: A phase III study of the Southern Italy Cooperative Oncology Group (SICOG).

P. Ascierto, E. Simeone, M. G. Chiofalo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma

G. Botti, P. Ascierto, E. Simeone, 2013, Journal of Translational Medicine.

Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group

V. Lorusso, M. Roselli, C. Sandomenico, 2009, Cancer Chemotherapy and Pharmacology.

Oxaliplatin (OXA) plus folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus (OXAFAFU) versus irinotecan (IRI) plus FA and FU i.v. bolus (IRIFAFU) in advanced colorectal carcinoma (ACC): Activity and toxicity results of the SICOG 0103 randomized trial.

G. Filippelli, S. Tafuto, F. De Vita, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment

R. Bianco, D. Melisi, A. Zaniboni, 2024, Cancer medicine.